Successful treatment of Alcaligenes xylosoxidans in automated peritoneal dialysis-related peritonitis [1]

Peritoneal Dialysis International

Volumn 27, Issue 5, 2007, Pages 596-598

  Ledger, S G ^a   Cordy, P ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; DIALYSIS FLUID; DIANEAL; GENTAMICIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ACHROMOBACTER XYLOSOXIDANS; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AUTOMATION; BACTERIUM CULTURE; CASE REPORT; CLINICAL FEATURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIABETIC NEPHROPATHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; HYPERTENSION; KIDNEY FAILURE; LETTER; NEPHROSCLEROSIS; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; RISK FACTOR; SINGLE DRUG DOSE; ALCALIGENES; CHRONIC KIDNEY FAILURE; GRAM NEGATIVE INFECTION; ISOLATION AND PURIFICATION; MICROBIOLOGY;

AGED; ALCALIGENES; CIPROFLOXACIN; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMIPENEM; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; PERITONITIS;

EID: 38449091407     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080702700524     Document Type: Letter

References (10)

1. Tang S, Cheng C, Tse K, Li F, Choy B, Chan T, et al. CAPD-associated peritonitis caused by Alcaligenes xylosoxidans sp. xylosoxidans. Am J Nephrol 2001; 21:502-6.
2. Melgosa M, Espinazo O, Alonso A, Garcia Perea A, Navaro M. Dialysis-associated Alcaligenes xylosaxidans peritonitis: a pediatric case. Perit Dial Int 2004; 24:72-5.
3. El-Shahawy M, Kim D, Gadallah MF, Peritoneal dialysis-associated peritonitis caused by Alcaligenes xylosoxidans. Am J Nephrol 1998; 18:452-5.
4. Ingra-Sieman Y, Chmel H, Cobbs C. Clinical and laboratory characteristics of Achromobacter xylosoxidans infection. J Clin Microbial 1980; 11:141-5.
5. Reveredy M, Freney J, Fleurette J, Coulet M, Surgot M, Marmet D, et al. Nosocomial colonization and infection by Achromobacter xylosoxidans. J Clin Microbiol 1984; 19: 140-3.
6. Morrison A, Boyce K. Peritonitis caused by Alcaligenes xylosoxidans: case report and review of the literature. J Clin Microbiol 1986; 24:879-81.
7. Haqqie S, Roth M, Bailie G. Unsuccessful treatment of CAPD peritonitis caused by Alcaligenes xylosoxidans subsp. denitrificans. Ren Fail 1995; 17:611-14.
8. Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25: 107-31.
9. Schaefer F, Klaus G, Muller-Wiefel D, Mehls O. Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis. The Mid-European Pediatric Dialysis Study Group (MEPPS). J Am Soc Nephrol 1999; 10: 136-45.
10. Low C, Gopalakrishna K, Lye W. Pharmacokinetics of once daity intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 2000; 11: 1117-21.